Boosting Response: The Impact of Immune Checkpoint Inhibitors on Radiation Treatment Schedules
DOI:
https://doi.org/10.17140/CSMMOJ-2-e002Abstract
The recent FDA approvals of immunomodulatory drugs such as Nivoluvamab (Opdivo), Pembrolizumab (Keytruda) and Ipilimumab (Yervoy) for treatment of Non-small cell lung cancer (NSCLC) and melanoma have renewed interest in cancer immunotherapy. Initial attempts to activate the immune system to improve anti-tumor immunity by vaccination and/ or cytokine treatments failed due to low response rates and high toxicity.1,2 However, improved knowledge of interactions between tumor cells and the immune system has led to a change in strategy. Recently, it has been shown that tumors activate immune checkpoint pathways which suppress any anti tumor immune responses.3 Immune checkpoint inhibitors block these pathways and can evoke the power of cytotoxic CD8+ T lymphocytes to eliminate cancer cells.
References
Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, da-carbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the East-ern Cooperative Oncology Group. J Clin Oncol. 2008; 26(35): Page e9 5748-5754. doi: 10.1200/JCO.2008.17.5448
Eton O, Legha SS, Bedikian AY, et al. Sequential biochemo-therapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002; 20(8): 2045-2052. doi: 10.1200/JCO.2002.07.044
Gajewski TF, Schreiber H, Fu YX. Innate and adaptive im-mune cells in the tumor microenvironment. Nat Immunol. 2013; 14(10): 1014-1022. doi: 10.1038/ni.2703
Peng W, Liu C, Xu C, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemo-kines. Cancer Res. 2012; 72(20): 5209-5218. doi: 10.1158/0008- 5472.CAN-12-1187
Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528): 568-571. doi: 10.1038/nature13954
Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maxi-mizing tumor immunity with fractionated radiation. Int J Ra-diat Oncol Biol Phys. 2012; 83(4): 1306-1310. doi: 10.1016/j. ijrobp.2011.09.049
Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A. Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett. 2015. doi: 10.1016/j.can-let.2015.03.024
Victor TSC, Rech AJ, Maity A, et al. Radiation and dual check-point blockade activate non-redundant immune mechanisms in cancer. Nature. 2015; 520(7547): 373-377. doi: 10.1038/na-ture14292
Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by con-current PD-L1 blockade. Cancer Res. 2014; 74(19): 5458-5468. doi: 10.1158/0008-5472.CAN-14-1258
Seung SK, Curti BD, Crittenden M, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and im-munological responses. Sci Transl Med. 2012; 4(137): 137ra74. doi: 10.1126/scitranslmed.3003649
Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012; 366(10): 925-931. doi: 10.1056/NEJ-Moa1112824
Ohri N, Dicker AP, Lawrence YR. Can drugs enhance hypo-fractionated radiotherapy? A novel method of modeling radio-sensitization using in vitro data. Int J Radiat Oncol Biol Phys. 2012; 83(1): 385-393. doi: 10.1016/j.ijrobp.2011.06.1990 Cancer Stud Mol Med Open J Page e10
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
